[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635123":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":23,"collaborators":10,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":10,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":10,"maxAge":10,"enrollmentInfo":35,"targetDuration":38,"studyType":39,"phases":10,"briefSummary":40,"conditions":41,"keywords":10,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":10},{"fullName":5,"class":6},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Plasma Device Group",null,"Patients receiving standard scar care (silicone gel, pressure therapy, scar cream, etc.) plus plasma device therapy. The plasma device is applied non-contact to the scar area at a distance of 5-10 mm, with power set to low\u002Fmedium mode according to scar type. Treatment duration: 5-10 seconds per cm², total not exceeding 15 minutes per session. Frequency: once every 2 weeks, total 4-6 sessions as one course. After each session, repair dressing or antibiotic ointment is applied.",[13],"Device: Plasma Device",{"label":15,"type":10,"description":16,"interventionNames":10},"Conventional Treatment Group","Patients receiving standard scar care alone, including silicone gel, pressure therapy, scar cream, etc., without plasma device therapy. Participants may be enrolled concurrently (not receiving plasma device) or identified retrospectively from medical records. Propensity score matching will be used to control for confounding factors.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DEVICE","Plasma Device","Cold atmospheric plasma device used for non-contact scar treatment. The device generates low-temperature plasma that modulates fibroblast proliferation, promotes collagen remodeling, reduces inflammation, and improves local microcirculation.",[9],{"type":24,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Hu Zhicheng","Professer","100635123","plasma-therapy-for-scar-management-100635123",false,"NCT07548593","Plasma Therapy for Scar Management","A Prospective, Multicenter, Real-World Observational Study of a Plasma Device for the Treatment of Hypertrophic Scars, Keloids, Atrophic Scars, Postoperative Scars, and Burn Scars","Inclusion Criteria:\n\n* Clinical diagnosis of scar requiring therapeutic intervention, including but not limited to hypertrophic scar, keloid, atrophic scar, postoperative linear scar, burn scar, post-traumatic scar, or post-acne scar.\n* Scar duration ≥ 3 months, in stable or proliferative phase.\n* Age ≥ 12 years (for minors under 18 years, informed consent must be provided by a parent or legal guardian).\n* Stable vital signs and able to tolerate scar treatment.\n* Understand and willing to participate and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Active infection, ulceration, or malignant tumor involving the scar area. Severe uncontrolled systemic disease or major organ dysfunction (heart, lung, brain, etc.).\n* Psychiatric disorder that prevents compliance with treatment.\n* Presence of diseases (malignant tumor, autoimmune disease) or use of medications (high-dose corticosteroids: ≥40 mg prednisone or equivalent per day for ≥2 weeks) that may affect scar healing or assessment.\n* HIV positivity, clinical diagnosis of AIDS, or absolute neutrophil count (ANC) \\\u003C 1000 cells\u002Fmm³ during screening.\n* Pregnancy or breastfeeding.\n* Previous treatment of the scar area (e.g., laser, injection, surgery) without a washout period of ≥3 months.","ALL",{"count":36,"type":37},800,"ESTIMATED","6 Months","OBSERVATIONAL","This study is a prospective, multicenter, real-world observational study. It aims to evaluate whether adding plasma device therapy to standard scar care is effective and safe for treating various types of scars, including hypertrophic scars, keloids, atrophic scars, postoperative scars, burn scars, and post-traumatic scars. A total of 400 patients receiving standard scar care plus plasma therapy will be enrolled from multiple hospitals across China. Their outcomes will be compared with 400 matched patients who received standard scar care alone. The main outcomes include change in Vancouver Scar Scale (VSS) score, pruritus relief, pain relief, scar thickness reduction, patient satisfaction, recurrence rate at 6 months, and any side effects. Patients will be followed for up to 6 months after treatment completion.",[42],"Wound Healing","NOT_YET_RECRUITING","2026-04-22",{"date":46,"type":47},"2026-04-27","ACTUAL",{"date":49,"type":37},"2026-05-01",{"date":51,"type":37},"2026-12-31",{"name":5,"class":6}]